Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 1/20 | 0.53 |
| ▸ | MMP2 | P08253 | 1/20 | 0.50 |
| ▸ | MMP13 | P45452 | 1/20 | 0.50 |
| ▸ | MMP14 | P50281 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 4/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.47 |
| ▸ | CDC7 | O00311 | 1/20 | 0.47 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4436705 | 0.87 | KDM4E (0.55) | RAB9ANPC1ALDH1A1KDM4EKMT2A | |
| SCHEMBL1750739 | 0.86 | CASP1 (0.60) | MMP2MMP13MMP14RAB9ANPC1 | |
| SCHEMBL11248675 | 0.84 | MAPT (0.45) | RAB9ANPC1ALDH1A1CYP2C19CYP2C9 | |
| SCHEMBL1816625 | 0.84 | ALPL (0.64) | ALKMMP2MMP13MMP14RAB9A | |
| SCHEMBL11242562 | 0.81 | CDK5 (0.43) | MMP13RAB9ANPC1ALDH1A1CDC7 | |
| SCHEMBL4853168 | 0.80 | ALDH1A1 (0.58) | ALKALDH1A1CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL20471292 | 0.80 | ALPL (0.70) | RAB9ANPC1ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL7275274 | 0.80 | ALPL (0.53) | RAB9ANPC1ALDH1A1KDM4EMEN1 | |
| SCHEMBL11253347 | 0.80 | ALDH1A1 (0.48) | RAB9ANPC1ALDH1A1KDM4EMEN1 | |
| SCHEMBL11239797 | 0.80 | POLB (0.44) | RAB9ANPC1ALDH1A1KDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130012485-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2013-01-10 | — | — | US | disclosed |
| EP-2124913-A1 | 1-AMINOMETHYL- L- PHENYL- CYCLOHEXANE DERIVATIVES AS DDP-IV INHIBITORS | Novartis AG (CH) | 2009-12-02 | — | — | EP | disclosed |
| US-7462613-B2 | Pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-12-09 | — | — | US | disclosed |
| US-7462613-B2 | Pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-12-09 | — | — | US | disclosed |
| US-7462613-B2 | Pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-12-09 | — | — | US | disclosed |
| WO-2008077597-A1 | 1-AMINOMETHYL- L- PHENYL- CYCLOHEXANE DERIVATIVES AS DDP-IV INHIBITORS | NOVARTIS AG (CH) | 2008-07-03 | — | — | WO | disclosed |
| US-7309701-B2 | Pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-12-18 | — | — | US | disclosed |
| US-7309701-B2 | Pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-12-18 | — | — | US | disclosed |
| US-7309701-B2 | Pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-12-18 | — | — | US | disclosed |
| EP-1611121-B1 | PYRIDAZINONE DERIVATIVES AS CDK2-INHIBITORS | AVENTIS PHARMA SA (FR) | 2007-08-08 | — | — | EP | disclosed |
| EP-1611121-A1 | PYRIDAZINONE DERIVATIVES AS CDK2-INHIBITORS | Aventis Pharma S.A. (FR) | 2006-01-04 | — | — | EP | disclosed |
| EP-1581505-A1 | PYRIDAZINONE DERIVATIVES AS GSK-3BETA INHIBITORS | Sanofi-Aventis Deutschland GmbH (DE) | 2005-10-05 | — | — | EP | disclosed |
| US-20050026918-A1 | Novel pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2005-02-03 | — | — | US | disclosed |
| US-20040176377-A1 | Novel pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2004-09-09 | — | — | US | disclosed |
| WO-2004046117-A1 | PYRIDAZINONE DERIVATIVES AS GSK-3BETA INHIBITORS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-06-03 | — | — | WO | disclosed |
| WO-2004046130-A1 | PYRIDAZINONE DERIVATIVES AS CDK2-INHIBITORS | AVENTIS PHARMA S.A. (FR) | 2004-06-03 | — | — | WO | disclosed |
| US-4346221-A | Preparation of 4-amino-6-(pyridinyl)-3(2H)-pyridazinones from 6-(pyridinyl)-3(2H)-pyridazinones | STERLING DRUG INC. (US) | 1982-08-24 | — | — | US | disclosed |
| US-4338446-A | Di-(lower-alkyl)hydroxy-[2-oxo-2-(pyridinyl)ethyl]-propanedioates | STERLING DRUG INC. (US) | 1982-07-06 | — | — | US | disclosed |
| US-4305943-A | 4-Amino-6-(pyridinyl)-3(2H)-pyridazinones and their use as cardiotonics | STERLING DRUG INC. (US) | 1981-12-15 | — | — | US | disclosed |
| US-4304776-A | 4-Substituted-6-(pyridinyl)-3(2h)-pyridazinones and their use as intermediates and cardiotonics | STERLING DRUG INC. (US) | 1981-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176377-A1 | Novel pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them | ADRA2C, ADRA1A, ADRA1B | ALK 405/4885MMP2 4581/4885MMP13 4078/4885 |
| US-20050026918-A1 | Novel pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them | C5, ADRA2C, ADRA1A | ALK 176/4885MMP2 3980/4885MMP13 3817/4885 |
| US-20130012485-A1 | ORGANIC COMPOUNDS | DPP4, DPP3, DPP7 | ALK 576/4885MMP2 19/4885MMP13 184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.